DK2528940T3 - Fremgangsmåder til intracellulær omdannelse af enkeltkædede proteiner til deres to-kædeform - Google Patents

Fremgangsmåder til intracellulær omdannelse af enkeltkædede proteiner til deres to-kædeform

Info

Publication number
DK2528940T3
DK2528940T3 DK11702755.7T DK11702755T DK2528940T3 DK 2528940 T3 DK2528940 T3 DK 2528940T3 DK 11702755 T DK11702755 T DK 11702755T DK 2528940 T3 DK2528940 T3 DK 2528940T3
Authority
DK
Denmark
Prior art keywords
chain
methods
proteins
intracellular conversion
chain form
Prior art date
Application number
DK11702755.7T
Other languages
English (en)
Inventor
Sanjiv Ghanshani
Linh Q Le
Yi Liu
Lance E Steward
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2528940T3 publication Critical patent/DK2528940T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11702755.7T 2010-01-25 2011-01-24 Fremgangsmåder til intracellulær omdannelse af enkeltkædede proteiner til deres to-kædeform DK2528940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28696310P 2010-01-25 2010-01-25
PCT/US2011/022272 WO2011091370A1 (en) 2010-01-25 2011-01-24 Methods of intracellular conversion of single-chain proteins into their di-chain form

Publications (1)

Publication Number Publication Date
DK2528940T3 true DK2528940T3 (da) 2014-07-14

Family

ID=44146329

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11702755.7T DK2528940T3 (da) 2010-01-25 2011-01-24 Fremgangsmåder til intracellulær omdannelse af enkeltkædede proteiner til deres to-kædeform

Country Status (24)

Country Link
US (3) US8546108B2 (da)
EP (3) EP2684890B1 (da)
JP (2) JP5956350B2 (da)
KR (1) KR101930962B1 (da)
CN (1) CN102822196B (da)
AU (1) AU2016204285B2 (da)
BR (1) BR112012018526A2 (da)
CA (1) CA2788074C (da)
CL (1) CL2012002087A1 (da)
CY (2) CY1115341T1 (da)
DK (1) DK2528940T3 (da)
ES (2) ES2488217T3 (da)
HK (1) HK1179634A1 (da)
HU (1) HUE029962T2 (da)
IL (2) IL221095A (da)
MX (1) MX2012008650A (da)
NZ (1) NZ601472A (da)
PL (2) PL2684890T3 (da)
PT (2) PT2528940E (da)
RU (1) RU2569185C2 (da)
SG (1) SG182691A1 (da)
SI (2) SI2684890T1 (da)
WO (1) WO2011091370A1 (da)
ZA (1) ZA201205793B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091370A1 (en) * 2010-01-25 2011-07-28 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9096886B2 (en) * 2011-03-11 2015-08-04 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
EP3822286A1 (en) * 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
RU2627181C2 (ru) * 2015-12-29 2017-08-03 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Экспрессионный плазмидный лентивирусный вектор для гетерологичной экспрессии рекомбинантного человеческого белка cd47
US10308927B2 (en) 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
CN109055339B (zh) * 2018-09-19 2020-09-01 生工生物工程（上海）股份有限公司 Tev蛋白酶突变体、基因、生物材料、制备方法、试剂或试剂盒和应用
WO2020073553A1 (zh) * 2018-10-10 2020-04-16 上饶市康可得生物科技有限公司 筛选蛋白酶变体的方法以及获得的蛋白酶变体
CN111019925B (zh) * 2018-10-10 2022-08-23 上饶市康可得生物科技有限公司 筛选蛋白酶变体的方法以及获得的蛋白酶变体
CN111019926B (zh) * 2018-10-10 2021-11-26 上饶市康可得生物科技有限公司 Tev蛋白酶变体、其融合蛋白及制备方法和用途
JP7296660B2 (ja) * 2018-10-10 2023-06-23 上饒市康可得生物科技有限公司 Ｔｅｖプロテアーゼバリアント、その融合タンパク質、調製方法および使用
KR20200080749A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 N-말단의 메티오닌이 절단된 목적 단백질 발현용 유전자 발현 카세트 및 이를 이용하여 n-말단의 메티오닌이 절단된 목적 단백질을 생산하는 방법
JP6867452B2 (ja) * 2019-08-09 2021-04-28 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
WO2021062063A1 (en) * 2019-09-26 2021-04-01 Chan Zuckerberg Biohub, Inc. Improved variants of tev protease for biotechnological applications
CN113801866B (zh) * 2021-09-02 2022-08-16 无锡佰翱得生物科学有限公司 一种高效表达具有高活性及稳定性的重组tev酶及其制备方法和应用
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4321618A1 (en) * 2022-08-09 2024-02-14 NUMAFERM GmbH Variants of tev protease and uses thereof
CN116640196B (zh) * 2023-05-10 2024-02-06 山东农业大学 囊泡相关膜蛋白的相关蛋白vap1在抗马铃薯y病毒中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180529T3 (es) 1990-02-26 2003-02-16 Univ Leland Stanford Junior Identificacion y expresion de secuencias de adn de un receptor de esteroides de insectos.
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
EP0745121B1 (en) 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6746859B1 (en) 1993-01-15 2004-06-08 Genetics Institute, Llc Cloning of enterokinase and method of use
DE69432787D1 (de) 1993-01-15 2003-07-10 Inst Genetics Llc Klonierung von Enterokinase und Verfahren zu deren Verwendung
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
CN1373802A (zh) 1999-07-22 2002-10-09 宝洁公司 在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7132529B2 (en) 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US6836976B2 (en) 2003-03-18 2005-01-04 Solveig Laura Haugland Collapsible outdoor footwear and backpack
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1761558A1 (en) 2004-06-30 2007-03-14 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
JP2008508886A (ja) 2004-08-04 2008-03-27 アラーガン、インコーポレイテッド 活性ボツリヌス毒素ａ型の発現の最適化
US7892565B2 (en) 2004-09-01 2011-02-22 Allergan, Inc. Degradable clostridial toxins
US20060099710A1 (en) * 2004-11-10 2006-05-11 Donnelly Mark I Vector for improved in vivo production of proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US20080031931A1 (en) 2006-03-17 2008-02-07 Andover Healthcare, Inc. Organotellurium and selenium-based antimicrobial formulations and articles
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
CA2657521A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP1897887A1 (de) * 2006-09-08 2008-03-12 Universitätsklinikum Freiburg Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung
ES2425413T3 (es) * 2006-11-22 2013-10-15 Novo Nordisk A/S Método para preparar carboxipeptidasa activada
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
WO2010040134A2 (en) * 2008-10-04 2010-04-08 University Of Medicine And Dentistry Of New Jersey Independently inducible system of gene expression
WO2011091370A1 (en) * 2010-01-25 2011-07-28 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form

Also Published As

Publication number Publication date
EP2684890B1 (en) 2016-04-20
IL246310B (en) 2018-11-29
CL2012002087A1 (es) 2013-01-11
AU2011207445A1 (en) 2012-08-30
ZA201205793B (en) 2013-05-29
JP5956350B2 (ja) 2016-07-27
KR20120134117A (ko) 2012-12-11
AU2016204285B2 (en) 2018-03-29
HK1179634A1 (en) 2013-10-04
WO2011091370A1 (en) 2011-07-28
JP6312745B2 (ja) 2018-04-18
PT2528940E (pt) 2014-06-24
SI2684890T1 (sl) 2016-10-28
CN102822196A (zh) 2012-12-12
AU2016204285A1 (en) 2016-07-14
JP2013517797A (ja) 2013-05-20
US8546108B2 (en) 2013-10-01
US20140030759A1 (en) 2014-01-30
EP2528940B1 (en) 2014-05-14
CY1115341T1 (el) 2017-01-04
JP2016164205A (ja) 2016-09-08
CN102822196B (zh) 2014-12-17
KR101930962B1 (ko) 2018-12-19
MX2012008650A (es) 2012-11-23
BR112012018526A2 (pt) 2020-09-08
ES2488217T3 (es) 2014-08-26
US9340813B2 (en) 2016-05-17
RU2012136227A (ru) 2014-03-10
US20160319265A1 (en) 2016-11-03
US9938514B2 (en) 2018-04-10
ES2592856T3 (es) 2016-12-01
EP3034511A1 (en) 2016-06-22
PL2528940T3 (pl) 2014-10-31
EP2528940A1 (en) 2012-12-05
NZ601472A (en) 2013-08-30
PT2684890T (pt) 2016-07-28
IL246310A0 (en) 2016-07-31
IL221095A (en) 2017-06-29
US20120295330A1 (en) 2012-11-22
PL2684890T3 (pl) 2016-11-30
CA2788074A1 (en) 2011-07-28
EP2684890A1 (en) 2014-01-15
RU2569185C2 (ru) 2015-11-20
HUE029962T2 (hu) 2017-04-28
CY1117797T1 (el) 2017-05-17
SI2528940T1 (sl) 2014-07-31
CA2788074C (en) 2016-07-12
SG182691A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
DK2528940T3 (da) Fremgangsmåder til intracellulær omdannelse af enkeltkædede proteiner til deres to-kædeform
CY2017025I2 (el) Αντιδοτα αντιπηκτικων
DK2771364T3 (da) Fremstilling af heterodimere proteiner
DK3824991T3 (da) Fremgangsmåde til forberedelse af lithiumsulfat
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
CO7010824A2 (es) Inhibidores de aplicación viral
DK2678283T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til deres fremstilling
DK2874506T3 (da) Fremgangsmåde til fremstilling af enzymgranulater
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2560683T4 (da) Fremstilling af heteromultimeriske proteiner
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
DK2676118T3 (da) Fremgangsmåde til fiksering af vævsprøve
DK2569438T3 (da) Fremgangsmåde til fremstilling af biogas
DK2793895T3 (da) Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter
DK3133157T3 (da) Fremgangsmåde til oprensning af vitamin k-afhængige proteiner
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
BR112014003352A2 (pt) métodos para fabricação de construções estruturais
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
DK2580339T3 (da) Fremgangsmåde til fremstilling af biobrændstoffer